Koji Sakamoto

Koji Sakamoto

Auto-generated profile, based on publicly available information

Koji Sakamoto

Department of Otorhinolaryngology, Saiseikai Utsunomiya Hospital, Utsunomiya, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2014 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RFRyoichi Fujii
Ryoichi Fujii
YIYorihisa Imanishi
Yorihisa Imanishi
KSKatsushi Shibata
Katsushi Shibata
NSNobuya Sakai
Nobuya Sakai
KSKoji Sakamoto
Koji Sakamoto
KOKaoru Ogawa
Kaoru Ogawa
The epithelial-to-mesenchymal transition (EMT) accompanied by the downregulation of E-cadherin has been thought to promote metastasis. Cyclooxygenase-2 (Cox-2) is presumed to contribute to cancer progression through its multifaceted function, and recently its inverse relationship with E-cadherin was suggested. The aim of the present study was to investigate whether selective Cox-2 inhibitors restore the expression of E-cadherin in head and neck squamous cell carcinoma (HNSCC) cells, and to examine the possible correlations of the expression levels of EMT-related molecules with clinicopathological factors in HNSCC.

19 October 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
NHNoboru Habu
Noboru Habu
YIYorihisa Imanishi
Yorihisa Imanishi
KKKaori Kameyama
Kaori Kameyama
MSMasayuki Shimoda
Masayuki Shimoda
YTYutaka Tokumaru
Yutaka Tokumaru
KOKaoru Ogawa
Kaoru Ogawa
The side population (SP) of cancer cells is reportedly enriched with cancer stem cells (CSCs), however, the functional role and clinical relevance of CSC marker molecules upregulated in the SP of head and neck squamous carcinoma (HNSCC) cells are yet to be elucidated. Patients with clinical stage I/II (T1-2N0M0) tongue squamous cell carcinoma (TSCC) typically undergo partial glossectomy; however, development of delayed neck metastasis (DNM) tends to reduce their survival. In the present study, we aimed to determine the CSC markers in the SP of HNSCC cells along with their functions in cellular behaviors, and to clarify the association of these markers with DNM. Flow cytometry was applied to isolate SP from main population (MP) in HNSCC cells. The expression of the CSC markers was examined by semi-quantitative RT-PCR and immunocytochemistry. In vitro proliferation, migration, and invasion assays were performed to assess cellular behaviors. Clinicopathological factors and immunohistochemical expressions of Oct3/4 and Nanog were evaluated using surgical specimens from 50 patients with stage I/II TSCC. SPs were isolated in all three cell lines examined. Expression levels of Oct3/4 and Nanog were higher in SP cells than MP cells. Additionally, cell migration and invasion abilities were higher in SP cells than MP cells, whereas there was no difference in proliferation. Univariate analysis showed that expression of Oct3/4 and Nanog, vascular and muscular invasion, and mode of invasion were significantly correlated with DNM. Multivariate logistic regression revealed that Oct3/4 expression (risk ratio = 14.78, p = 0.002) and vascular invasion (risk ratio = 12.93, p = 0.017) were independently predictive of DNM. Regarding the diagnostic performance, Oct3/4 showed the highest accuracy, sensitivity, and NPV of 82.0 %, 61.5 %, and 86.8 %, respectively, while vascular invasion showed the highest specificity and PPV of 94.6 % and 71.4 %, respectively. These results suggest that Oct3/4 and Nanog represent probable CSC markers in HNSCC, which contribute to the development of DNM in part by enhancing cell motility and invasiveness. Moreover, along with vascular invasion, expression of Oct3/4 can be considered a potential predictor for selecting patients at high risk of developing DNM.

26 June 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YIYorihisa Imanishi
Yorihisa Imanishi
HOHiroyuki Ozawa
Hiroyuki Ozawa
KSKoji Sakamoto
Koji Sakamoto
RFRyoichi Fujii
Ryoichi Fujii
SSSeiji Shigetomi
Seiji Shigetomi
KOKaoru Ogawa
Kaoru Ogawa
Transoral videolaryngoscopic surgery (TOVS) was developed as a new distinct surgical procedure for hypopharyngeal cancer (HPC) and supraglottic cancer (SGC) staged at up to T3. However, long-term treatment outcomes of TOVS remain to be validated. Under a straight broad intraluminal view provided by combined use of a distending laryngoscope and a videolaryngoscope, we performed en bloc tumor resection via direct bimanual handling of the ready-made straight-form surgical instruments and devices. We retrospectively analyzed functional and oncologic outcomes of 72 patients with HPC (n = 58) or SGC (n = 14) whose minimum follow-up was 24 months or until death. The cohort comprised nine patients of Tis, 23 of T1, 33 of T2, and 7 of T3. Among 36 patients (50%) who underwent neck dissection simultaneously, all but one were pathologically node-positive. Twelve patients underwent postoperative concurrent chemoradiation (CCRT) as adjuvant treatment, and another four patients underwent radiation or CCRT for second or later primary cancer. The endotracheal tube was removed in an operation room in all but two patients who underwent temporary tracheostomy. Pharyngeal fistula was formed transiently in two patients. The median time until patients resumed oral intake and could take a soft meal was 2 and 5 days, respectively. Eventually, 69 patients (96%) took normal meals. The 5-year cause-specific survival (CSS), overall survival (OS), larynx-preserved CSS, and loco-regional controlled CSS were 87.3%, 77.9%, 86.0%, and 88.0%, respectively. Multivariate analysis revealed N2-3 as an independent prognostic factor in both CSS (hazard ratio [HR] = 25.51, P = 0.008) and OS (HR = 4.90, P = 0.022), which indirectly reflected higher risk of delayed distant metastasis. Considering its sound functional and oncological outcomes with various practical advantages, TOVS can be a dependable, less invasive, and cost-effective surgical option of an organ-function preservation strategy for HPC and SGC.

1 January 2007 in Toukeibu Gan
Verified
Journal Article
Closed access
TTToshiki Tomita
Toshiki Tomita
KSKoji Sakamoto
Koji Sakamoto
RFRyoichi Fujii
Ryoichi Fujii
HOHiroyuki Ozawa
Hiroyuki Ozawa
KOKaoru Ogawa
Kaoru Ogawa
MFMasato Fujii
Masato Fujii

1 January 2014 in AUDIOLOGY JAPAN
Verified
Journal Article
Closed access
HOHiroshi Okazaki
Hiroshi Okazaki
SSSeiichi Shinden
Seiichi Shinden
DSDaisuke Suzuki
Daisuke Suzuki
KSKoji Sakamoto
Koji Sakamoto
TNTakanori Nishiyama
Takanori Nishiyama
KOKaoru Ogawa
Kaoru Ogawa
要旨: 補聴器装用経験のない両側感音難聴患者25例に対して, 初回から時間を限定せず出来るだけ長く補聴器を装用する指導を試みた。その結果, 購入に至った23例は貸出しの翌日から平均11時間の装用ができ, 以後3か月間を通して11時間以上が継続された。非購入2例中, 音に慣れずに中断した1例はほとんど装用できなかったが, 経済的理由で中断した1例は平均10時間以上の装用が可能であった。補聴器の音に対する慣れの評価はVisual Analog Scale (VAS) を用いた。週ごとのVAS平均値は1週目には約50, 5週目には約80, 8週目には約90であった。このことから補聴器の音に十分に慣れるまでには, 約2ヶ月かかることが示唆された。今回の結果からは, 長時間装用を継続したことで補聴器の音に慣れたと言えるものであった。早期から長時間装用することは患者が早く装用効果を実感できるとともに積極的な補聴器の音の増幅を可能にし, 患者と調整者の両方にメリットをもたらすものと考えられた。

1 January 2015 in Practica oto-rhino-laryngologica. Suppl.
Verified
Journal Article
Closed access
Takanori NishiyamaTakanori Nishiyama
Takanori Nishiyama
KSKoji Sakamoto
Koji Sakamoto
FIFumihiro Ito
Fumihiro Ito
SSSeiichi Shinden
Seiichi Shinden
KOKaoru Ogawa
Kaoru Ogawa
When a thyroid nodule has malignant features found by some examinations (e.g. Echo, FNAC, CT), we perform surgical resection. But if the thyroid nodule does not have malignant feature, there is still the possibility of malignancy, especially when the nodule is large. In the case of large pre-operatively benign thyroid nodules, we therefore consider a diagnostic lobectomy. There is, however, no definite recommendation how large a nodule should be before a lobectomy is performed, and how many malignancies exist in pre-operatively benign nodules. In our hospital, we consider surgical resection when the diameter of the thyroid nodule is over 3 cm. In this study, we analyze pre-operatively benign thyroid nodules in which surgical resection was performed in our hospital, how many malignant nodules there were and what the characteristics were between benign or malignant nodule. From 2005 April to 2012 June, 351 patients underwent a lobectomy in our hospital, 70 of which were pre-operatively benign thyroid nodules with diameters of over 3 cm. We analyzed the pathological findings and compared the nodule diameters, serum thyroglobulin, FNAC’s classification and some characteristics of echography between pathologically benign and malignant cases. Fifty-eight patients (83%) had pathologically benign nodules, and 12 patients (17%) had malignant nodules. In 58 benign nodules, 33 nodules (47%) were adenomatous goiter, 24 patients (34%) had follicular adenomas and 1 nodule (1%) was an atypical adenoma. In the 12 malignant patients, 8 patients (11%) had papillary adenocarcinoma and 4 patients (6%) had follicular adenocarcinoma. Almost no significant characteristics were found concerning malignancy, in diameter, serum thyroglobulin, class of FNAC and features of echography. As for complications after surgery, hypothyroidism occured in four patients (6%), and neither hypoparathyroidism nor vocal fold paralysis occurred. We concluded that pre-operatively benign thyroid nodule that were over 3 cm in diameter had about a 17% possibility of malignancy. Examinations may not distinguish whether such pre-operatively benign tumors are benign or malignant before surgical resection. We should therefore consider whether to perform therapeutic surgery or not in such patients.